Cite
Human pharmacokinetics prediction with an in vitro–in vivo correction factor approach and in vitro drug-drug interaction profile of bictegravir, a potent integrase-strand transfer inhibitor component in approved biktarvy® for the treatment of HIV-1 infection
MLA
Subramanian, Raju, et al. Human Pharmacokinetics Prediction with an in Vitro–in Vivo Correction Factor Approach and in Vitro Drug-Drug Interaction Profile of Bictegravir, a Potent Integrase-Strand Transfer Inhibitor Component in Approved Biktarvy® for the Treatment of HIV-1 Infection. Jan. 2023. EBSCOhost, https://doi.org/10.6084/m9.figshare.21963275.
APA
Subramanian, R., Wang, J., Murray, B., Custodio, J., Hao, J., Lazerwith, S., Staiger, K. M., Mwangi, J., Sun, H., Tang, J., Wang, K., Rhodes, G., Wijaya, S., Zhang, H., & Smith, B. J. (2023). Human pharmacokinetics prediction with an in vitro–in vivo correction factor approach and in vitro drug-drug interaction profile of bictegravir, a potent integrase-strand transfer inhibitor component in approved biktarvy® for the treatment of HIV-1 infection. https://doi.org/10.6084/m9.figshare.21963275
Chicago
Subramanian, Raju, Jianhong Wang, Bernard Murray, Joseph Custodio, Jia Hao, Scott Lazerwith, Kelly MacLennan Staiger, et al. 2023. “Human Pharmacokinetics Prediction with an in Vitro–in Vivo Correction Factor Approach and in Vitro Drug-Drug Interaction Profile of Bictegravir, a Potent Integrase-Strand Transfer Inhibitor Component in Approved Biktarvy® for the Treatment of HIV-1 Infection,” January. doi:10.6084/m9.figshare.21963275.